Progression-free survival (PFS) and time to treatment failure (TTF) analysis by the time-series behavior of neutrophil-to-lymphocyte ratio (NLRseries).

<p>Kaplan-Meier survival curves for the PFS (A, C) and TTF (B, D) according to the level of NLRseries (A, B) after the first cycle of treatment and (C, D) after the second cycle of treatment. Solid line, an increase of >30% NLR (iNLR); Dashed line, stable or decrease NLR (sNLR).</p

Overall survival (OS) analysis by the response to nivolumab.

<p>Kaplan-Meier survival curves for the OS according to the response to nivolumab. Solid line, progressive disease (PD); Dashed line, stable disease (SD) and partial response (PR).</p

Overall survival (OS) and progression-free survival (PFS) analysis by the baseline (NLRpre) and post-treatment neutrophil-to-lymphocyte ratio (NLRpost).

<p>Kaplan-Meier survival curves for the OS (A, C) and PFS (B, D) according to the level of NLRpre (A, B) and the NLRpost (C, D). Solid line, NLR ≤ 5; Dashed line, NLR > 5.</p

Swimmers plot detailing progression survival (PFS) and overall survival (OS).

<p>Swimmers plot illustrating overall survival of all individual patients in this study. Survival is divided into two periods: PFS (gray) and OS (black). →, alive at last follow-up; ◆, discontinued due to toxicity.</p

Studies of the efficacy of the baseline NLR for advanced NSCLC.

<p>Studies of the efficacy of the baseline NLR for advanced NSCLC.</p

Patient characteristics and clinicopathological data.

<p>Patient characteristics and clinicopathological data.</p